Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02763644 · ClinicalTrials.gov registry record · Phase 2
Efficacy and Safety of LFG316 in Transplant Associated Microangiopathy (TAM) Patients
A Phase 2 study, sponsored by Novartis Pharmaceuticals.
- Terminated
- Registry status
- Phase 2
- Development phase
- 7
- Enrollment target
NCT02763644 is a Phase 2 study that was terminated before completion, run by Novartis Pharmaceuticals. The registered enrollment target is 7 participants.
The verdict
NCT02763644, a Phase 2 study, was terminated before completion, sponsored by Novartis Pharmaceuticals.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 7 participants
- Enrollment target
Study Summary
This was a randomized, SoC-controlled, open-label, multi-center study in patients with TAM after hematopoietic precursor cell transplantation (HPCT) . Study consisted of up to 28 days of screening period, 16 weeks treatment period that can be extended to 45 weeks.Approximately 40 patients was to be randomized to receive SoC or LFG316 plus SoC. Patients was included in the study if they have diagnosis of TAM and poor prognostic markers. This trial was terminated: LFG316, a monoclonal antibody inhibitor of complement factor 5 (C5), had been studied in seven patients with transplantation-associated microangiopathy (TAM). Due to low confidence of clinical benefit, this study was closed
Interventions
- OTHER Standard of care treatment
- DRUG LFG316 active drug
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 7 participants |
| Start Date | 2016-04-22 |
| Est. Completion | 2017-06-30 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02763644
The ClinicalTrials.gov registry entry for NCT02763644 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 7 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novartis Pharmaceuticals, which has 1,375 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Standard of care treatment is the first listed.
NCT02763644 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02763644 about?
NCT02763644 is a clinical study titled "Efficacy and Safety of LFG316 in Transplant Associated Microangiopathy (TAM) Patients". This was a randomized, SoC-controlled, open-label, multi-center study in patients with TAM after hematopoietic precursor cell transplantation (HPCT) . Study consisted of up to 28 days of screening period, 16 weeks treatment period that can be extended to 45 weeks.Approximately 40 patients was to be...
What is the current status of trial NCT02763644?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 7 participants. The study started on 2016-04-22. Estimated completion is 2017-06-30.
What interventions are being tested in trial NCT02763644?
The interventions under investigation include: Standard of care treatment (OTHER), LFG316 active drug (DRUG).
Who is sponsoring clinical trial NCT02763644?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.